FDA Grants De Novo Clearance to AI-Powered Ultrasound Technology for Predicting Delivery Dates
核心洞察
Ultrasound AI (搜索) received FDA De Novo clearance for its Delivery Date AI (搜索) technology, a cloud-based system that predicts delivery dates using standard ultrasound images.
The AI system demonstrated remarkable accuracy with a 0.92 R² value in predicting days to delivery in a study of over 5,700 patients published in The Journal of Maternal-Fetal & Neonatal Medicine.
The technology is designed to aid clinical decision-making in pregnancies where traditional dating methods are unreliable and aims to reduce the burden of preterm birth (搜索).
Ultrasound AI (搜索) has received FDA De Novo clearance for its flagship Delivery Date AI (搜索) technology, marking a significant advancement in prenatal care technology. The cloud-based Software as a Medical Device (SaMD) determines a Predicted Delivery Date (PDD) solely from standard ultrasound images and integrates seamlessly into current obstetrics and maternal-fetal medicine prenatal visit workflows.
Clinical Validation and Performance
The technology has undergone rigorous clinical evaluation through the peer-reviewed PAIR (Perinatal Artificial Intelligence in Ultrasound) Study, published in The Journal of Maternal-Fetal & Neonatal Medicine and conducted in collaboration with the University of Kentucky. The landmark study of more than 5,700 patients demonstrated remarkable accuracy of 0.92 R² value in predicting days to delivery using only standard ultrasound images.
Trained on millions of de-identified ultrasound images across diverse pregnancies and clinical settings, the technology leverages an ensemble of deep-learning neural networks to analyze entire ultrasound images, including fetal and maternal characteristics correlated with delivery timing.
Addressing Clinical Needs
The technology serves as an adjunctive tool designed to aid clinical decision-making in pregnancies where traditional dating methods, including last menstrual period and/or ultrasound gestational-age dating, are unreliable. "Delivery Date AI (搜索) isn't just innovative; it's a clinically evaluated tool that helps clinicians reduce uncertainty and better support mothers and families," said Robert Bunn, President and Founder of Ultrasound AI (搜索).
Dr. Nathan Fox, board-certified OBGYN and Maternal Fetal Medicine specialist, emphasized the clinical significance: "Fetal development and delivery timing impact nearly every decision in obstetrics. Delivery Date AI (搜索) gives clinicians unprecedented insight into a pregnancy's progression, allowing us to make more informed decisions for how and when we intervene."
Implementation and Accessibility
The system is designed for practical implementation across diverse healthcare settings. Delivery Date AI (搜索) is compatible with most existing ultrasound machines, can be installed in minutes, and delivers results in seconds after image upload. With minimal onboarding and no workflow disruption, the technology is scalable across high-volume health systems, resource-constrained clinics, and obstetric deserts.
The image-first approach supports equitable care across diverse populations and clinical settings, while offering the potential to reduce downstream costs associated with preterm birth (搜索). The technology complements clinical judgment by turning ultrasound imaging data into actionable insights that support individualized care planning and follow-up.
Market Availability
With FDA clearance, Delivery Date AI (搜索) is now available to practices, hospitals, imaging centers, and ultrasound equipment partners across the United States. The FDA decision is available on their website, representing what Bunn described as "a major milestone in our mission to reduce the burden of preterm birth (搜索) by supporting earlier, more informed clinical decision-making."